基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD8⁺ 淋巴细胞与肿瘤浸润抑制性 FOXP3⁺ 效应调节性 T 细胞的比值与浸润性乳腺癌治疗反应相关
英文原题：The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer.
查看英文原题
The ratio of CD8 + lymphocytes to tumor-infiltrating suppressive FOXP3 + effector regulatory T cells is associated with treatment response in invasive breast cancer.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
高 CD8/eTreg 比值可提高浸润性乳腺癌患者的 pCR 率。
研究思路结论见上方概要
目的
FOXP3+和CD8+是乳腺癌TIL（肿瘤浸润淋巴细胞）（TILs）的公认标志物。FOXP3+TILs由效应性Tregs（eTregs）和其他亚群组成，这些亚群根据其抑制功能的差异进行分类。在这项前瞻性研究中，我们评估了乳腺癌中的Treg亚群和CD8+TILs。
方法
共纳入84例乳腺癌患者。提取新鲜TILs，并通过流式细胞术将Tregs分为eTregs（CD4 + FOXP3 high CD45RA -）、其他FOXP3 + Treg亚群（na ve和非Tregs）以及总CD8 + CD4 - TILs。分析各Treg亚群的抑制强度。评估TIL亚群、临床病理特征与化疗反应之间的关联。
结果
CD8/eTreg 比值平均值为 7.86（四分位距：4.08-12.80）。与其他亚群相比，eTregs 的增殖功能受到显著抑制（增殖率：对照：89.3%，+ naiiveTreg：64.2%，+ non-Treg：78.2% vs eTreg 1.93%；所有 P < 0.05）。CD8+/eTreg 比值高的患者在新辅助化疗中获得了优异的病理完全缓解（pCR）率（90.2%），且 CD8/eTreg 比值是 pCR 的独立预测因素（比值比：18.7（置信区间 1.25-279）P < 0.05）。对每位接受 NAC 的患者进行 CD8/eTreg 比值的详细评估显示，在间质 TILs < 50% 的三阴性亚型患者中，高 CD8/eTreg 比值患者的 pCR 率显著高于低 CD8/FOXP3 比值患者（39.6% vs 13.3，P < 0.05）。
展开英文摘要原文
PURPOSE
FOXP3 + and CD8 + are recognized markers of tumor-infiltrating lymphocytes (TILs) for breast cancer. FOXP3 + TILs are composed of effector Tregs (eTregs) and other subpopulations that are classified by their differences in suppressive function. In this prospective study, we evaluated Treg subpopulations and CD8 + TILs in breast cancer.
METHODS
84 patients with breast cancer were enrolled. Fresh TILs were extracted andTregs were classified into eTregs (CD4 + FOXP3 high CD45RA - ), other FOXP3 + Treg subsets (na ve and non-Tregs), and total CD8 + CD4 - TILs using flow cytometry. The suppression strength of each Treg subpopulation was analyzed. The association between TIL subpopulations, clinicopathological characteristics, and response to chemotherapy was evaluated.
RESULTS
The mean CD8/eTreg ratio value was 7.86 (interquartile range: 4.08-12.80). The proliferation function of eTregs was significantly suppressed compared with that of the other subpopulations (proliferation rates: control: 89.3%, + naiiveTreg: 64.2%, + non-Treg: 78.2% vs eTreg 1.93%; all P < 0.05). The patients with high with a high CD8 + /eTreg ratio achieved excellent pathological complete response (pCR) rate of neoadjuvant chemotherapy (90.2%) and the CD8/eTreg ratio were independent predictive factors for pCR (odds ratio:18.7(confidence interval 1.25-279) P < 0.05). A detailed assessment of the CD8/eTreg ratio for each patient who underwent NAC revealed that high CD8/eTreg ratio showed a significantly higher pCR rate compared to patients with a low CD8/FOXP3 ratio (39.6% vs 13.3, P < 0.05) in triple negative subtype patients with stromal TILs < 50%.
CONCLUSIONS
A high CD8/eTreg ratio enhances pCR rate in patients with invasive breast cancer.
论文信息
- 作者
- Goda N、Sasada S、Shigematsu H、Masumoto N、Arihiro K、Nishikawa H、Sakaguchi S、Okada M
- 第一作者单位
- Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan.Japan
- 通讯作者单位
- Department of Surgical Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan. takayukikadoya@gmail.com.Japan
- 期刊
- Discover oncology2022 Apr 19
- 原文标识
- PubMed 35438346 · DOI 10.1007/s12672-022-00482-5
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →